The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo

Ma,Zhikun; Yao,Guoliang; Zhou,Bo; Fan,Yonggang; Gao,Shegan; Feng,Xiaoshan

doi:10.3892/mmr.2012.999

The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo

Authors:
- Zhikun Ma
- Guoliang Yao
- Bo Zhou
- Yonggang Fan
- Shegan Gao
- Xiaoshan Feng
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of the Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China, Department of General Surgery, The First Affiliated Hospital of the Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
Published online on: July 20, 2012 https://doi.org/10.3892/mmr.2012.999
Pages: 897-903

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

AZD7762, a novel checkpoint kinase 1 (Chk 1)inhibitor, has been proven to sensitize various tumor cells to DNA damage. However, whether or not AZD7762 sensitizes breast cancer cells to radiation has not been defined. In the present study, we aimed to demonstrate for the first time, that AZD7762 not only promotes radiation-induced apoptosis and mitotic catastrophe of p53 mutant T47D breast cancer cells in vitro, but also delays their xenograft growth in response to radiation in vivo. Our mechanistic study showed that AZD7762 treatment resulted in the abrogation of radiation-induced G2/M arrest and the inhibition of radiation damage repair as demonstrated by increased radiation-induced γH2AX expression and decreased RAD51 protein expression. These results suggest that AZD7762 may effectively abrogate radiation-induced G2/M arrest and inhibit radiation damage repair in conferring radiosensitivity on p53 mutant T47D breast cancer cells, by promoting radiation-induced apoptosis and mitotic catastrophe. The clinical application of AZD7762, as an adjuvant in the radiotherapy of breast cancers, should be further explored.

View Figures

View References

1	Truong PT, Olivotto IA, Whelan TJ and Levine M: Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ. 170:1263–1273. 2004. View Article : Google Scholar : PubMed/NCBI
2	Bartelink H, Horiot JC, Poortmans P, et al: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 345:1378–1387. 2001. View Article : Google Scholar
3	Liu Q, Guntuku S, Cui XS, et al: Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14:1448–1459. 2000.PubMed/NCBI
4	Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
5	Gao Q, Huang X, Tang D, et al: Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. Apoptosis. 11:1789–1800. 2006. View Article : Google Scholar : PubMed/NCBI
6	Bartek J and Lukas J: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 3:421–429. 2003. View Article : Google Scholar : PubMed/NCBI
7	Koniaras K, Cuddihy AR, Christopoulos H, Hogg A and O’Connell MJ: Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene. 20:7453–7463. 2001. View Article : Google Scholar : PubMed/NCBI
8	Syljuasen RG, Sorensen CS, Hansen LT, et al: Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol. 25:3553–3562. 2005. View Article : Google Scholar : PubMed/NCBI
9	Pan Y, Ren KH, He HW and Shao RG: Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis. Cancer Biol Ther. 8:1559–1566. 2009. View Article : Google Scholar : PubMed/NCBI
10	Chen Z, Xiao Z, Gu WZ, et al: Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer. 119:2784–2794. 2006. View Article : Google Scholar : PubMed/NCBI
11	Zabludoff SD, Deng C, Grondine MR, et al: AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 7:2955–2966. 2008. View Article : Google Scholar : PubMed/NCBI
12	Mitchell JB, Choudhuri R, Fabre K, et al: In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res. 16:2076–2084. 2010. View Article : Google Scholar : PubMed/NCBI
13	Bucher N and Britten CD: G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 98:523–528. 2008. View Article : Google Scholar : PubMed/NCBI
14	Morgan MA, Parsels LA, Zhao L, et al: Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70:4972–4981. 2010. View Article : Google Scholar : PubMed/NCBI
15	Maity A, McKenna WG and Muschel RJ: The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol. 31:1–13. 1994. View Article : Google Scholar : PubMed/NCBI
16	Held KD: Radiation-induced apoptosis and its relationship to loss of clonogenic survival. Apoptosis. 2:265–282. 1997. View Article : Google Scholar : PubMed/NCBI
17	Vakifahmetoglu H, Olsson M and Zhivotovsky B: Death through a tragedy: mitotic catastrophe. Cell Death Differ. 15:1153–1162. 2008. View Article : Google Scholar : PubMed/NCBI
18	Brown JM and Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 5:231–237. 2005.PubMed/NCBI
19	Aris SM and Pommier Y: Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762. Cancer Res. 72:979–989. 2012. View Article : Google Scholar : PubMed/NCBI
20	Vance S, Liu E, Zhao L, et al: Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle. 10:4321–4329. 2011. View Article : Google Scholar : PubMed/NCBI
21	Bartucci M, Svensson S, Romania P, et al: Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 19:368–378. 2011.PubMed/NCBI
22	Yang H, Yoon SJ, Jin J, et al: Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy. Biochem Biophys Res Commun. 406:53–58. 2011. View Article : Google Scholar : PubMed/NCBI
23	Wilsker D, Chung JH and Bunz F: Chk1 suppresses bypass of mitosis and tetraploidization in p53-deficient cancer cells. Cell Cycle. 11:1564–1572. 2012. View Article : Google Scholar : PubMed/NCBI
24	Origanti S, Cai SR, Munir AZ, White LS and Piwnica-Worms H: Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene. Mar 19–2012.(E-pub ahead of print).
25	Tse AN, Sheikh TN, Alan H, Chou TC and Schwartz GK: 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol Pharmacol. 75:124–133. 2009. View Article : Google Scholar : PubMed/NCBI
26	Jia XZ, Yang SY, Zhou J, et al: Inhibition of CHK1 kinase by Go6976 converts 8-chloro-adenosine-induced G2/M arrest into S arrest in human myelocytic leukemia K562 cells. Biochem Pharmacol. 77:770–780. 2009. View Article : Google Scholar : PubMed/NCBI
27	Eriksson D and Stigbrand T: Radiation-induced cell death mechanisms. Tumour Biol. 31:363–372. 2010. View Article : Google Scholar : PubMed/NCBI
28	Roninson IB, Broude EV and Chang BD: If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 4:303–313. 2001. View Article : Google Scholar : PubMed/NCBI
29	Kesari S, Advani SJ, Lawson JD, et al: DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. Future Oncol. 7:1335–1346. 2011. View Article : Google Scholar : PubMed/NCBI
30	McNeely S, Conti C, Sheikh T, et al: Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle. 9:995–1004. 2010. View Article : Google Scholar : PubMed/NCBI
31	O’Connor MJ, Martin NM and Smith GC: Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene. 26:7816–7824. 2007.PubMed/NCBI
32	Tao ZF and Lin NH: Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med Chem. 6:377–388. 2006. View Article : Google Scholar : PubMed/NCBI
33	Ashwell S, Janetka JW and Zabludoff S: Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs. 17:1331–1340. 2008. View Article : Google Scholar : PubMed/NCBI